
ERRATUM

ASCO presentations highlight value of cancer biomarkers

Alisa Opar

Nature Reviews Drug Discovery 7, 547–549 (July 2008) | doi:10.1038/nrd2633

This article stated that: "Clinicians are looking at tackling that challenge by combining 'irreversible' EGFR inhibitors, such as Exelixis's XL647, with agents that inhibit another kinase, MET, such as XL184, a multitargeted kinase inhibitor also developed by Exelixis."

There is an error in this sentence as Exelixis's EGFR inhibitor XL647 is in fact a reversible EGFR inhibitor. The correct version is: "Clinicians are looking at tackling that challenge by combining EGFR inhibitors, such as Exelixis's XL647, with agents that inhibit another kinase, MET, such as XL184, a multitargeted kinase inhibitor also developed by Exelixis."